山东大学耳鼻喉眼学报 ›› 2025, Vol. 39 ›› Issue (6): 54-64.doi: 10.6040/j.issn.1673-3770.0.2024.021

• 论著 • 上一篇    

基于Web of Science进行生物制剂治疗慢性鼻窦炎文献计量学分析

李阳松1,2,袁发洋1,2,杨艳1,2,张田1,2,喻国冻1,2   

  1. 1.贵州医科大学附属医院 耳鼻咽喉头颈外科, 贵州 贵阳 550004;
    2.贵州医科大学临床医学院, 贵州 贵阳 550004
  • 发布日期:2025-11-19
  • 通讯作者: 喻国冻. E-mail:yuguodongent@163.com
  • 基金资助:
    国家自然科学基金资助项目(82260219)

Bibliometric analysis of biologic agents for the treatment of chronic rhinosinusitis based on the Web of Science database

LI Yangsong1,2, YUAN Fayang1,2, YANG Yan1,2, ZHANG Tian1,2, YU Guodong1,2   

  1. 1. Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China2. Department of Clinical Medicine, Guizhou Medical University, Guiyang 550004, Guizhou, China
  • Published:2025-11-19

PDF (PC)

27

摘要： 目的 通过文献计量学分析,探讨生物制剂治疗慢性鼻窦炎的研究现状、热点及发展趋势,以期为该领域的研究提供参考。 方法 检索Web of Science核心合集数据库中2004—2023年生物制剂治疗慢性鼻窦炎的相关文献,基于CiteSpace和VOSviewer软件对纳入文献进行国家或地区、机构、作者、关键词、期刊及文献共被引进行分析。 结果 共纳入761篇文献,发文量整体呈上升趋势;发文量最多的国家、机构、作者分别是美国、根特大学、Bachert C;该领域最高产的期刊是《国际过敏与鼻科学论坛》《过敏与临床免疫学杂志-实践》;研究热点主要集中在生物制剂在慢性鼻窦炎伴鼻息及哮喘中的应用,以及慢性鼻窦炎的病理生理;研究前沿主要集中在度普利尤单抗及美泊利珠单抗。 结论 生物制剂用于慢性鼻窦炎的治疗疗效明确,逐渐得到广大学者的重视,具有良好的应用前景。

关键词: 慢性鼻窦炎, 生物制剂, 文献计量学, 可视化分析, Web of Science

Abstract: Objective Through bibliometric analysis, this paper discussed the research status, hotspots, and development trends of biological agents in the treatment of chronic rhinosinusitis to provide a reference for research in this field. Methods Relevant literatures on the treatment of chronic rhinosinusitis with biological agents from 2004 to 2023 were retrieved from the Web of Science core collection database were retrieved. Using CiteSpace and VOSviewer software, the included literature was analyzed by country/region, institution, author, keyword, journal, and literature co-citation. Results A total of 761 articles were included, and the total number of articles was increasing. The countries, institutions and authors with the highest number of publications were the United States, Ghent University and Bachert C. The top journals in this field are International Forum of Allergy & Rhinology and Journal of Allergy And Clinical Immunology-InPractice; the research hotspots mainly focus on the application of biological agents in chronic rhinosinusitis with nasal polyps and asthma, as well as the pathophysiology of chronic rhinosinusitis; the research frontiers mainly focus on dupilumab and mepolizumab. Conclusion The curative effect of biological agents in the treatment of chronic rhinosinusitis is clear, which has gradually attracted the attention of scholars and has a good prospect of application.

Key words: Chronic rhinosinusitis, Biologics, Bibliometric, Visual analysis, Web of Science

中图分类号: 

  • R459.9
[1] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(2): 81-100. doi:10.3760/cma.j.issn.1673-0860.2019.02.001 Subspecialty Group of Rhinology Editorial Board of Chinese Journal of Otorhinolaryngology Head, Neck Surgery;Subspecialty Group of Rhinology Society of Otorhinolaryngology Head, NECK Surgery. Chinese guidelines for diagnosis and treatment of chronic rhinosinusitis(2018)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019, 54(2): 81-100. doi:10.3760/cma.j.issn.1673-0860.2019.02.001
[2] Bachert C, Bhattacharyya N, Desrosiers M, et al. Burden of disease in chronic rhinosinusitis with nasal polyps[J]. J Asthma Allergy, 2021, 14: 127-134. doi:10.2147/jaa.s290424
[3] Brzost J, Czerwaty K, D(·overz)aman K, et al. Perspectives in therapy of chronic rhinosinusitis[J]. Diagnostics(Basel), 2022, 12(10): 2301. doi:10.3390/diagnostics12102301
[4] De Corso E, Settimi S, Montuori C, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review[J]. Acta Otorhinolaryngol Ital, 2023, 43(suppl. 1): S3-S13. doi:10.14639/0392-100x-suppl.1-43-2023-01
[5] 石帅, 郑泉. 度普利尤单抗在慢性鼻窦炎伴鼻息肉治疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 36-42. doi:10.6040/j.issn.1673-3770.0.2021.565 SHI Shuai, ZHENG Quan. Research advances of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 36-42. doi:10.6040/j.issn.1673-3770.0.2021.565
[6] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(suppl s29): 1-464. doi:10.4193/rhin20.600
[7] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209): 1638-1650. doi:10.1016/s0140-6736(19)31881-1
[8] Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial[J]. JAMA, 2016, 315(5): 469-479. doi:10.1001/jama.2015.19330
[9] Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features[J]. Am J Respir Crit Care Med, 2004, 169(4): 459-467. doi:10.1164/rccm.200303-365oc
[10] Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology[J]. J Allergy Clin Immunol, 2013, 131(6): 1479-1490. doi:10.1016/j.jaci.2013.02.036
[11] Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for?[J]. J Pharm Pharm Sci, 2009, 12(3): 288-311. doi:10.18433/j3nc79
[12] Bal SM, Bernink JH, Nagasawa M, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs[J]. Nat Immunol, 2016, 17: 636-645. doi:10.1038/ni.3444
[13] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5): 1133-1141. doi:10.1016/j.jaci.2006.05.031
[14] Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis[J]. Annu Rev Pathol, 2017, 12: 331-357. doi:10.1146/annurev-pathol-052016-100401
[15] Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells[J]. Nature, 2018, 560: 649-654. doi:10.1038/s41586-018-0449-8
[16] Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype[J]. Clin Exp Allergy, 2009, 39(2): 193-202. doi:10.1111/j.1365-2222.2008.03157.x
[17] 李华斌, 赖玉婷. 慢性鼻-鼻窦炎的发病机制及诊疗进展[J]. 山东大学耳鼻喉眼学报, 2018, 4(3): 4-9. doi:10.6040/j.issn.1673-3770.1.2018.004 LI Huabin, LAI Yuting. Pathogenesis, diagnosis, and treatment of chronic rhinosinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 4(3): 4-9. doi:10.6040/j.issn.1673-3770.1.2018.004
[18] de Benedictis FM, Bush A. Janus looks both ways: how do the upper and lower airways interact?[J]. Paediatr Respir Rev, 2020, 34: 59-66. doi:10.1016/j.prrv.2019.06.004
[19] König IR, Fuchs O, Hansen G, et al. What is precision medicine?[J]. Eur Respir J, 2017, 50(4): 1700391. doi:10.1183/13993003.00391-2017
[20] Tai J, Han M, Kim TH. Therapeutic strategies of biologics in chronic rhinosinusitis: current options and future targets[J]. Int J Mol Sci, 2022, 23(10): 5523. doi:10.3390/ijms23105523
[21] Thamboo A, Kilty S, Witterick I, et al. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis[J]. J Otolaryngol Head Neck Surg, 2021, 50(1): 15. doi:10.1186/s40463-021-00493-2
[22] Zhang Y, Gevaert E, Lou HF, et al. Chronic rhinosinusitis in Asia[J]. J Allergy Clin Immunol, 2017, 140(5): 1230-1239. doi:10.1016/j.jaci.2017.09.009
[23] Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma[J]. J Allergy Clin Immunol Pract, 2021, 9(3): 1133-1141. doi:10.1016/j.jaip.2020.09.063
[24] Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis[J]. Ann Allergy Asthma Immunol, 2020, 124(4): 326-332. doi:10.1016/j.anai.2019.12.001
[25] Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps(CRSwNP)and biologics: Definitions and management[J]. J Allergy Clin Immunol, 2021, 147(1): 29-36. doi:10.1016/j.jaci.2020.11.013
[26] Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study[J]. J Allergy Clin Immunol, 2022, 149(3): 957-965. doi:10.1016/j.jaci.2021.07.045
[27] Roland LT, Smith TL, Schlosser RJ, et al. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop[J]. Int Forum Allergy Rhinol, 2020, 10(9): 1037-1042. doi:10.1002/alr.22633
[28] Brown WC, Senior B. A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis[J]. Curr Allergy Asthma Rep, 2020, 20(6): 16. doi:10.1007/s11882-020-00910-y
[29] 王成硕, 张罗. 慢性鼻窦炎伴鼻息肉进入生物制剂治疗时代[J]. 中华耳鼻咽喉头颈外科杂志, 2021, 56(10): 1023-1027. doi:10.3760/cma.j.cn115330-20210509-00260 WANG Chengshuo, ZHANG Luo. Biologics: a new option in treatment of chronic rhinosinusitis with nasal polyps[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021, 56(10): 1023-1027. doi:10.3760/cma.j.cn115330-20210509-00260
[30] Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma[J]. Allergy, 2019, 74(12): 2312-2319. doi:10.1111/all.13875
[31] 崇维琨, 王娟. 联合应用奥马珠单抗在儿童中重度变应性哮喘合并慢性鼻窦炎中的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 21-26. doi:10.6040/j.issn.1673-3770.0.2022.544 CHONG Weikun, WANG Juan. Efficacy of Omalizumab in children with moderate and severe allergic asthma and chronic sinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 21-26. doi:10.6040/j.issn.1673-3770.0.2022.544
[32] Rizzi A, Gammeri L, Cordiano R, et al. Therapeutic strategies to prevent the recurrence of nasal polyps after surgical treatment: an update and in vitro study on growth inhibition of fibroblasts[J]. J Clin Med, 2023, 12(8): 2841. doi:10.3390/jcm12082841
[33] Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117. doi:10.1016/s0140-6736(22)02420-5
[1] 张广玲,陈兴雪,武天义,孙占伟,王卫卫,李世超,王广科. Tespa1在慢性鼻窦炎伴鼻息肉中的表达及作用研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 35-42.
[2] 王紫燕,王方. 基于CiteSpace近10年单纯疱疹病毒性角膜炎的可视化分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 108-115.
[3] 王文晴,张丹,朱梦迪,王路阳,杨培培,孙思思,张秋敏,周慧. 慢性鼻窦炎伴鼻息肉复发手术时临床及组织病理学特征变化[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 46-53.
[4] 王奥维,时文杰. CRSwNP中医证型与TFH细胞相关因子的相关性研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 54-60.
[5] 张婕,尼玛吉宗,徐小东,周菁,刘建敏,罗依蕤,杜进涛,巴罗. 藏红花素在嗜酸性慢性鼻窦炎伴鼻息肉中调控2型炎症反应的研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 61-67.
[6] 张韵秋,任秀敏,徐鸥,董金辉,王建星. 奥马珠单抗靶向治疗慢性鼻窦炎伴鼻息肉的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 136-140.
[7] 李婷,赵冲,吴献. 鼻黏膜组织中miR-34a表达与慢性鼻窦炎患者术后复发的关系[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 20-25.
[8] 陈兴雪,张广玲,武天义,王卫卫,孙占伟,李世超,王广科. 抗IL-4Rα单克隆抗体与鼻内镜手术治疗嗜酸性粒细胞型慢性鼻窦炎伴鼻息肉的疗效分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 43-54.
[9] 张静祎,董湘依,牟亚魁,宋西成. 细胞焦亡在耳鼻咽喉科疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 140-148.
[10] 张诗涵,刘红兵. 基质金属蛋白酶对慢性鼻窦炎组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 116-123.
[11] 李霞,侯冉,王丽萍. 基于Web of Science近10年鼻腔冲洗治疗鼻腔疾病的文献计量学分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 52-60.
[12] 王佳慧,刘学勤. 全球近10年干眼相关生活质量研究——基于VOSviewer和CiteSpace的文献计量学及可视化分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 61-72.
[13] 崇维琨,王娟. 联合应用奥马珠单抗在儿童中重度变应性哮喘合并慢性鼻窦炎中的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 21-26.
[14] 王明明,罗洋,贺少娟,张现兴,李学忠. 慢性鼻窦炎鼻息肉基底干细胞转录组生物信息学分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 6-15.
[15] 王晓嫒,张欠欠,程翔宇,李志鹏,张维天,叶海波. 翼管神经切断术治疗2型慢性鼻窦炎伴过敏性鼻炎的临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 42-49.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发